Literature DB >> 20502393

Patient-delivered partner treatment and Trichomonas vaginalis repeat infection among human immunodeficiency virus-infected women.

Megan Gatski1, Leandro Mena, Judy Levison, Rebecca A Clark, Harold Henderson, Norine Schmidt, Susan L Rosenthal, David H Martin, Patricia Kissinger.   

Abstract

BACKGROUND: Repeat infections with Trichomonas vaginalis (TV) among human immunodeficiency virus (HIV)-infected women are common and may increase the risk of HIV transmission. Patient delivered partner treatment (PDPT) has been shown to reduce repeat infections of other sexually transmitted diseases. The purpose of this study was to evaluate adherence to PDPT and possible causes of repeat TV infection among HIV-infected women.
METHODS: A multicentered cohort study was conducted in 3 US cities. Women coinfected with HIV and TV were treated with metronidazole and given treatment to deliver to all reported sex partners. A test-of-cure visit was conducted 6 to 12 days post index treatment completion and behavioral data were collected.
RESULTS: Of 252 women (mean age = 40 years, s.d. 9.1) enrolled, 92.5% were black, 26.2% had CD4 cell counts <200/mm(3), 34.1% had plasma viral loads >10,000 copies, 58.3% were taking antiretrovial therapy, and 15.1% had multiple partners. Of the 183 women with partners at baseline, 75.4% provided PDPT to all partners and 61.7% reported they were sure all of their partners took the medication. Factors associated with not giving medications to all partner(s) were multiple sex partners, being single, and having at least one partner unaware of the index woman's HIV status. At test-of-cure, 10.3% were TV-positive and 16.7% reported having sex since baseline. Of the 24 repeat infections, 21 (87.5%) reported adherence to medication and no sexual exposure.
CONCLUSION: HIV-infected women with TV reported high adherence to PDPT, and treatment failure was the most common probable cause of repeat infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20502393      PMCID: PMC3805268          DOI: 10.1097/OLQ.0b013e3181d891fc

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  24 in total

1.  Metronidazole-resistant vaginal trichomoniasis--an emerging problem.

Authors:  J D Sobel; V Nagappan; P Nyirjesy
Journal:  N Engl J Med       Date:  1999-07-22       Impact factor: 91.245

2.  Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic.

Authors:  G Schmid; E Narcisi; D Mosure; W E Secor; J Higgins; H Moreno
Journal:  J Reprod Med       Date:  2001-06       Impact factor: 0.142

3.  Late recurrence of resistant Trichomonas vaginalis vaginitis: relapse or re-infection?

Authors:  M Kanno; J D Sobel
Journal:  Sex Transm Infect       Date:  2003-06       Impact factor: 3.519

4.  Trichomonas vaginalis and amplification of HIV-1 transmission.

Authors:  F Sorvillo; P Kerndt
Journal:  Lancet       Date:  1998-01-17       Impact factor: 79.321

5.  The relationship of cocaine use and human immunodeficiency virus serostatus to incident sexually transmitted diseases among women.

Authors:  T E Wilson; H Minkoff; J DeHovitz; J Feldman; S Landesman
Journal:  Sex Transm Dis       Date:  1998-02       Impact factor: 2.830

Review 6.  Trichomonas vaginalis, HIV, and African-Americans.

Authors:  F Sorvillo; L Smith; P Kerndt; L Ash
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

7.  Trichomoniasis: clinical manifestations, diagnosis and management.

Authors:  H Swygard; A C Seña; M M Hobbs; M S Cohen
Journal:  Sex Transm Infect       Date:  2004-04       Impact factor: 3.519

8.  Studies of adhesion of lymphocytic cells: implications for sexual transmission of human immunodeficiency virus.

Authors:  R Pearce-Pratt; D M Phillips
Journal:  Biol Reprod       Date:  1993-03       Impact factor: 4.285

9.  Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women.

Authors:  Ruth E Tuomala; Peter T O'Driscoll; James W Bremer; Cheryl Jennings; Chong Xu; Jennifer S Read; Elaine Matzen; Alan Landay; Carmen Zorrilla; William Blattner; Manhattan Charurat; Deborah J Anderson
Journal:  J Infect Dis       Date:  2003-01-24       Impact factor: 5.226

10.  Trichomonas vaginalis among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity?

Authors:  Manya Magnus; Rebecca Clark; Leann Myers; Thomas Farley; Patricia J Kissinger
Journal:  Sex Transm Dis       Date:  2003-11       Impact factor: 2.830

View more
  12 in total

1.  The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women.

Authors:  Megan Gatski; David H Martin; Judy Levison; Leandro Mena; Rebecca A Clark; Mary Murphy; Harold Henderson; Norine Schmidt; Patricia Kissinger
Journal:  Sex Transm Infect       Date:  2011-01-29       Impact factor: 3.519

2.  A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women.

Authors:  Patricia Kissinger; Leandro Mena; Judy Levison; Rebecca A Clark; Megan Gatski; Harold Henderson; Norine Schmidt; Susan L Rosenthal; Leann Myers; David H Martin
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12-15       Impact factor: 3.731

3.  Epidemiology and treatment of trichomoniasis.

Authors:  Patricia Kissinger
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

4.  The incidence of Trichomonas vaginalis infection in women attending nine sexually transmitted diseases clinics in the USA.

Authors:  Maria L Alcaide; Daniel J Feaster; Rui Duan; Stephanie Cohen; Chanelle Diaz; Jose G Castro; Matthew R Golden; Sarah Henn; Grant N Colfax; Lisa R Metsch
Journal:  Sex Transm Infect       Date:  2015-06-12       Impact factor: 3.519

5.  Sexually transmitted infection screening to prevent adverse birth and newborn outcomes: study protocol for a randomized-controlled hybrid-effectiveness trial.

Authors:  Andrew Medina-Marino; Susan Cleary; Christina A Muzny; Christopher Taylor; Ashutosh Tamhane; Phuti Ngwepe; Charl Bezuidenhout; Shelley N Facente; Koleka Mlisana; Remco P H Peters; Jeffrey D Klausner
Journal:  Trials       Date:  2022-05-24       Impact factor: 2.728

6.  Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  Patricia J Kissinger; Charlotte A Gaydos; Arlene C Seña; R Scott McClelland; David Soper; W Evan Secor; Davey Legendre; Kimberly A Workowski; Christina A Muzny
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 20.999

Review 7.  Trichomoniasis and HIV interactions: a review.

Authors:  Patricia Kissinger; Alys Adamski
Journal:  Sex Transm Infect       Date:  2013-04-20       Impact factor: 3.519

8.  The influence of ART on the treatment of Trichomonas vaginalis among HIV-infected women.

Authors:  Alys Adamski; Rebecca A Clark; Leandro Mena; Harold Henderson; Judy Levison; Norine Schmidt; Hirut T Gebrekristos; David H Martin; Patricia Kissinger
Journal:  Clin Infect Dis       Date:  2014-06-09       Impact factor: 9.079

Review 9.  A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.

Authors:  Elissa Meites; Charlotte A Gaydos; Marcia M Hobbs; Patricia Kissinger; Paul Nyirjesy; Jane R Schwebke; W Evan Secor; Jack D Sobel; Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2015-12-15       Impact factor: 9.079

10.  America's most distressed areas and their neglected infections: the United States Gulf Coast and the District of Columbia.

Authors:  Peter J Hotez
Journal:  PLoS Negl Trop Dis       Date:  2011-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.